Has John Winters, MD received payments from drug or device companies?

Yes. Drug and device makers reported $341,331 in general payments to John Winters, MD across 432 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Winters, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Winters, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Winters, MD

Hematology & Oncology · Westbrook, MENPI 1366648693

Payments from drug & device makers

$341,331in general payments, 2019–2025

Across 432 payments — averaging $790.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$90K
E.r. Squibb & Sons, L.L.C.$79K
Bristol Myers Squibb$47K
AstraZeneca$29K
Dova Pharmaceuticals$27K
Johnson & Johnson$13K
plus $56K from 44 others

$3,200in research payments, 2019–2025

Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$3K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	85	$90,184
E.r. Squibb & Sons, L.L.C.	74	$78,655
Bristol Myers Squibb	46	$47,415
AstraZeneca	34	$29,366
Dova Pharmaceuticals	17	$27,023
Johnson & Johnson	18	$13,028
Pharmacyclics LLC, An Abbvie Company	12	$8,191
Beigene USA, Inc.	9	$7,864
Seagen Inc.	17	$6,609
Genentech USA, Inc.	9	$3,891
Jazz Pharmaceuticals Inc.	11	$3,746
Eli Lilly	1	$3,500
Acceleron Pharma, Inc.	2	$3,200
Sanofi	6	$2,962
Epizyme, Inc.	3	$2,914
AbbVie	10	$2,665
Janssen Scientific Affairs, LLC	2	$2,034
GSK	5	$1,962
Pharmacosmos Therapeutics Inc.	3	$1,564
Innate Pharma, Inc	1	$1,200
Ipsen Biopharmaceuticals, Inc	1	$1,040
Agios Pharmaceuticals, Inc.	1	$750
Daiichi Sankyo Inc.	7	$180
ADC Therapeutics America, Inc.	4	$167
Novartis	8	$136
Baxter Healthcare	1	$124
Pfizer	5	$91
Lilly USA, LLC	4	$86
Stemline Therapeutics Inc.	4	$78
Genentech, Inc.	1	$77
Rigel Pharmaceuticals, Inc.	4	$71
Takeda Pharmaceuticals U.S.A., Inc.	2	$59
Merck	3	$48
EMD Serono, Inc.	2	$46
Sobi, Inc	2	$43
Novocure Inc.	1	$41
Eisai Inc.	2	$38
Astellas Pharma US Inc	2	$36
Caris MPI, Inc.	2	$33
Adaptive Biotechnologies Corporation	1	$31
Aimmune Therapeutics, Inc.	1	$31
Exelixis Inc.	1	$23
Regeneron Healthcare Solutions, Inc.	1	$23
Bayer	1	$22
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$18
Gilead	1	$17
Taiho Oncology, Inc.	1	$15
Acrotech Biopharma Inc.	1	$15
Amgen	1	$12
Clovis Oncology, Inc.	1	$11

How this compares

$341,331 in reported general payments places this provider in the 90th percentile of 60 hematology & oncology providers in Maine.

See all hematology & oncology providers in Maine →

Medicare billing

Part B allowed, 2024

$5,672,633

Medicare patients

603

Services billed

309,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Westbrook

Christian ThomasWestbrook$4.7M
Chiara BattelliWestbrook$1.5M
Matthew DuganWestbrook$675K
Devon EvansWestbrook$248K
Eleni NackosWestbrook$217K
Tracey WeisbergWestbrook$109K
Daniel RauschWestbrook$104K
Patrick BolandWestbrook$20K
Owen PickusWestbrook$1K
Anna NiegowskaPortland$2.7M

See the full list for Maine →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →